Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pliant Therapeutics, Inc.

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
From Pliant Therapeutics, Inc.
Via Globe NewsWire
Tickers PLRX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.